StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM
Leerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM
Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM
Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM
Eli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
November 23, 2016 6:51 AM
Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer's Disease Missed Primary Endpoint
November 23, 2016 6:45 AM
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
November 23, 2016 6:45 AM
